Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BioRay In-licenses Rights to Brain Cancer Drug from Nascent

publication date: May 19, 2021

BioRay Pharmaceutical, a Taizhou biotech, in-licensed rights to pritumumab, a potential treatment for brain cancer, from Nascent Biotech of San Diego. BioRay will pay up to $5 million for global pritumumab rights except for North America and Central America. Pritumumab is a natural human antibody that binds to vimentin, a protein expressed on the surface of epithelial cancers but not healthy cells. BioRay is the biologics subsidiary of China's Hisun Pharma. In 2019, PAG, a Hong Kong private equity firm, paid $540 million to acquire a 58% stake in BioRay. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital